Skip to Main Content

Amid a growing number of probes into the pharmaceutical industry, Mallinckrodt (MNK) tentatively agreed to pay $15.4 million to settle charges of illegal marketing by Questcor, a company that it purchased five years ago and was infamous for dramatically raising the price of a treatment for infantile spasms.

At the same time, however, the drug maker vowed to fight new claims by the Department of Justice that Questcor illegally used a charity to pay kickbacks aimed at encouraging Medicare patients to use the pricey medicine, which is known as Acthar Gel.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!